SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase III REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc.received approval of its Investigational Medicinal Product Dossier from the French regulatory authority, Agence Nationale de Sécurité du Médicament et des Produits de Santé, to advance in France its pivotal Phase III REGAL study of galinpepimut-S in patients with Acute Myeloid Leukemia who have achieved complete remission after second-line anti-leukemic therapy.
[SELLAS Life Sciences Group, Inc]
Press Release
Bookmark

No account yet? Register

Share

Bromodomain-Containing Protein 9 Promotes the Growth and Metastasis of Human Hepatocellular Carcinoma by Activating the TUFT1/AKT Pathway

BRD9 expression was found to be elevated in hepatocellular carcinoma (HCC) through data mining of public databases. Scientists confirmed that the expression of BRD9 was increased in HCC tissues compared with that in adjacent non-tumor tissues. The upregulated level of BRD9 was also observed in HCC cells in comparison to LO2 cells.
[Cell Death & Disease]
[zotpress userid=’6630899′ items=’CCKL8ILJ’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

All-Trans Retinoic Acid in Non-Promyelocytic Acute Myeloid Leukemia: Driver Lesion Dependent Effects on Leukemic Stem Cells

This authors summarize the role of all-trans retinoic acid in normal hematopoiesis and in acute myeloid leukemia (AML), focusing on its impact on AML stem cells.
[Cell Cycle]
[zotpress userid=’1254621′ items=’YWJUZZHZ’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

A Small Molecular Compound CC1007 Induces Cross-Lineage Differentiation by Inhibiting HDAC7 Expression and HDAC7/MEF2C Interaction in BCR-ABL Pre-B-ALL

The authors investigated the anticancer effects of CC1007 in breakpoint cluster region-Abelson 1 fusion gene-negative (BCR-ABL1) pre-B-ALL cell lines and primary patient-derived BCR-ABL1 pre-B-ALL cells.
[Cell Death & Disease]
[zotpress userid=’6445212′ items=’MHAM5JZM’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Efficacy of Tyrosine Kinase Inhibitors on a Mouse Chronic Myeloid Leukemia Model and Chronic Myeloid Leukemia Stem Cells

The authors evaluated the efficacy of ponatinib against chronic myeloid leukemia (CML) leukemic stem cells-containing lin Sca-1 +c-Kit + cells using a mouse CML-like model.
[Experimental Hematology]
[zotpress userid=’6807162′ items=’PLZHJ4R4′ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Ascentage Pharma’s BC-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia

Ascentage Pharma announced that the FDA has granted APG-2575, an Orphan Drug Designation for the treatment of chronic lymphocytic leukemia.
[Ascentage Pharma (PRNewswire,LLC)]
Press Release
Bookmark

No account yet? Register

Share

PRA Health Sciences Joins The Leukemia & Lymphoma Society on Global Trial for Children with Acute Leukemia

The Leukemia & Lymphoma Society and PRA Health Sciences announced a partnership to launch a first-of-its-kind global master clinical trial to develop new treatments for children with relapsed acute leukemia.
[The Leukemia & Lymphoma Society (PRNewswire,LLC)]
Press Release
Bookmark

No account yet? Register

Share

Mcl-1 Targeting Strategies Unlock the Proapoptotic Potential of TRAIL in Melanoma Cells

Scientists evaluated the involvement of antiapoptotic Bcl‐2 proteins in TNF‐related apoptosis‐inducing ligand (TRAIL) resistance. They were targeted by small interfering RNA‐mediated silencing in TRAIL‐sensitive and in TRAIL‐resistant melanoma cell lines.
[Molecular Carcinogenesis]
[zotpress userid=’6807162′ items=’JMSPDZL7′ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Better Leukemia-Free Survival with Allogeneic Than with Autologous HCT in AML Patients with Isolated Trisomy 8: A Study from the ALWP of the EBMT

Investigators compared outcomes of such patients given either allo-hematopoietic stem cell transplantation (HCT) or autologous (auto)-HCT. Inclusion criteria consisted of adult patients with de novo AML, isolated trisomy 8, first HCT between 2000 and 2018, CR1 at transplantation, and either auto-HCT or allo-HCT with a HLA-identical sibling donor or a 10/10 HLA-matched unrelated donor.
[Bone Marrow Transplantation]
[zotpress userid=’6445212′ items=’WQC9HU7′ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

STAT3 Transcription Factor as Target for Anti-Xancer Therapy

Authors summarize and discuss different drugs inhibiting the action of STAT3 and used in treatment of different types of cancer.
[Pharmacological Reports]
[zotpress userid=’6807162′ items=’VYAQBWQ7′ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

US Food and Drug Administration Approves Onureg® (Azacitidine Tablets), a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia

Bristol Myers Squibb announced that the FDA has approved Onureg® for the continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy and who are not able to complete intensive curative therapy.
[Bristol Myers Squibb, Inc.]
Press Release
Bookmark

No account yet? Register

Share
Share